This week’s Gene and Cell Therapy update highlights regulatory momentum, clinical progress across modalities, manufacturing innovation, and ongoing efforts to improve access and scalability globally.
In Today’s Newsletter
Dive deeper
🧬 FDA drafts genome editing safety guidance [1] [US • 14 Apr 2026]
https://clpmag.com/diagnostic-technologies/molecular-diagnostics/fda-draft-guidance-genome-editing-safety-ngs-2/
Context: Applies to ex vivo and in vivo genome editing products and supports IND and BLA submissions with standardized sequencing approaches [1].
Key point: FDA issued draft guidance recommending NGS-based methods to assess off-target editing and chromosomal integrity in gene therapy development [1].
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 GS-100 gains RMAT in NGLY1 deficiency [2] [US • 14 Apr 2026]
https://www.pharmiweb.com/press-release/2026-04-14/us-fda-grants-rmat-designation-to-gs-100-grace-science-s-gene-therapy-to-treat-ngly1-deficiency
Context: Open-label Phase 1/2/3 study (n=10) reported functional gains after ≥52 weeks (endpoint not specified) [2].
Key point: GS-100 (Grace Science; AAV9 gene therapy) received RMAT designation based on early clinical improvements in an ongoing trial [2].
Implication: May influence prescriber choice and payer reviews pending full data.
🏭 Andelyn–Evolyra partner on LGMD gene therapy manufacturing [3] [US • 14 Apr 2026]
https://www.prnewswire.com/news-releases/andelyn-biosciences-partners-with-evolyra-therapeutics-for-the-clinical-manufacturing-of-gene-therapies-for-the-treatment-of-limb-girdle-muscular-dystrophies-302740699.html
Context: Programs target LGMDR3 and LGMDR5 with planned IND submission in 2H 2026 (preclinical results cited) [3].
Key point: Andelyn Biosciences will provide IND-enabling and GMP manufacturing support for Evolyra’s AAVMYO2 gene therapies targeting LGMD subtypes [3].
Implication: Signals pipeline investment and modality expansion.
🧫 Stem cell therapy shows insulin independence in Type 1 diabetes [4] [India • 13 Apr 2026]
https://telanganatoday.com/a-clinical-trial-published-in-nejm-shows-stem-cell-based-living-pharmacy-treatment-may-eliminate-the-need-for-daily-insulin-in-type-1-diabetes-patients-most-participants-achieved-in
Context: Trial (n=12) used engineered cells that respond to glucose; immune suppression still required (duration 1 year) [4].
Key point: Stem cell-derived “living pharmacy” enabled most patients to discontinue insulin in an early clinical study [4].
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 CD83 CAR-T enters clinic in relapsed AML [5] [US • 14 Apr 2026]
https://www.roswellpark.org/newsroom/202604-roswell-park-launches-exclusive-cd83-car-t-cell-clinical-trial-patients-relapsed-or
Context: Therapy aims to selectively target leukemia cells while sparing healthy stem cells and may address GVHD (endpoint not specified) [5].
Key point: Roswell Park launched a first-in-human Phase 1 trial of CD83-targeting CAR-T in relapsed/refractory AML [5].
Implication: May influence prescriber choice and payer reviews pending full data.
🧪 Dual-target CAR-T strategy addresses antigen escape [6]
https://www.nature.com/articles/s41409-026-02858-5
Context: Approach integrates CAR-T with ASCT and multi-antigen targeting in hematologic malignancies (study design context) [6].
Key point: Sequential CD19 and CD22 CAR-T (“cocktail therapy”) described as feasible and may reduce relapse due to antigen escape [6].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
⚙️ Automated CAR-T manufacturing reaches first patients [7] [14 Apr 2026]
https://www.genengnews.com/topics/bioprocessing/car-t-cell-therapy-biomanufactured-by-cellares-infused-into-first-two-patients/
Context: Platform aims to improve scalability, consistency, and cost of autologous CAR-T production [7].
Key point: Cellares manufactured Cabaletta Bio’s rese-cel CAR-T and dosed first two patients using an automated platform [7].
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
⚡ Off-the-shelf CAR-T gains FDA Breakthrough designation [8] [US • 14 Apr 2026]
https://themedicinemaker.com/issues/2026/articles/april/fda-fast-tracks-off-the-shelf-car-t-for-aggressive-t-cell-cancers/
Context: Allogeneic CAR-T avoids manufacturing delays and targets aggressive T-cell leukemias/lymphomas (Phase 1 data context) [8].
Key point: WU-CART-007 (WashU Medicine; Wugen) received Breakthrough Therapy designation based on early clinical activity [8].
Implication: May influence prescriber choice and payer reviews pending full data.
💧 MeiraGTx to report 3-year xerostomia gene therapy data [9] [14 Apr 2026]
https://za.investing.com/news/company-news/meiragtx-to-present-3year-data-from-xerostomia-gene-therapy-trial-93CH-4210887
Context: Study evaluates safety and salivary function outcomes after one-time administration (duration 5-year follow-up) [9].
Key point: MeiraGTx will present 3-year follow-up data from Phase 1 AQUAx study of AAV-hAQP1 (results not yet disclosed) [9].
Implication: May influence prescriber choice and payer reviews pending full data.
🌍 India CGT perspective highlights access and cost barriers [10] [India • 13 Apr 2026]
https://www.springermedicine.com/gene-therapy/thalassemia/democratizing-the-cure-indigenous-innovations-and-the-future-of-/52284258
Context: Reviews pipeline, regulatory landscape, and adoption challenges for high-cost therapies [10].
Key point: Perspective highlights need for affordable, locally developed CGT solutions for pediatric diseases in India [10].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
Why It Matters
- FDA activity spans both regulatory frameworks and expedited pathways, reinforcing support for CGT innovation [1][2][8].
- Manufacturing and scalability, automated and allogeneic, remain central to improving CAR-T access [7][8].
- Clinical innovation continues across modalities, including stem cells, gene therapy, and CAR-T targeting strategies [4][5][6].
- Rare disease focus remains strong, especially in ultra-rare and genetic conditions with no approved therapies [2][3].
- Global access disparities, particularly in India, highlight cost and infrastructure as key constraints for CGT adoption [10].
📚 See the full Cell and Gene Therapy archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.
FAQ
What does the FDA genome editing guidance change?
It provides recommendations on using NGS to evaluate off-target edits and genome integrity in gene editing therapies, helping standardize preclinical safety packages for INDs and BLAs [1].
Why is GS-100 important for NGLY1 deficiency?
GS-100 is an AAV9 gene therapy with RMAT designation based on early clinical improvements in a small trial, targeting a disease with no approved treatments [2].
How is WU-CART-007 different from traditional CAR-T?
WU-CART-007 is an allogeneic, off-the-shelf CAR-T, enabling faster treatment without patient-specific manufacturing delays [8].
What is notable about the Type 1 diabetes stem cell study?
Engineered cells restored insulin production in most patients, though long-term immune suppression is still required [4].
Why does automated CAR-T manufacturing matter?
Platforms like Cellares’ aim to reduce cost and improve scalability, addressing key bottlenecks in autologous CAR-T access [7].
What is the rationale behind dual-target CAR-T (CD19/CD22)?
Targeting multiple antigens may reduce relapse from antigen escape and improve durability of response in B-cell malignancies [6].
Entities / Keywords
FDA, genome editing guidance, NGS, GS-100, Grace Science, NGLY1 deficiency, AAV9
Andelyn Biosciences, Evolyra Therapeutics, AAVMYO2, LGMD
stem cell therapy, Type 1 diabetes, living pharmacy
Roswell Park, CD83 CAR-T, AML
CD19/CD22 CAR-T, dual-target CAR-T, antigen escape
Cellares, Cell Shuttle™, Cabaletta Bio, rese-cel
WU-CART-007, WashU Medicine, Wugen, allogeneic CAR-T
MeiraGTx, AAV-hAQP1, xerostomia
India CGT, pediatric gene therapy access
References
- https://clpmag.com/diagnostic-technologies/molecular-diagnostics/fda-draft-guidance-genome-editing-safety-ngs-2/
- https://www.pharmiweb.com/press-release/2026-04-14/us-fda-grants-rmat-designation-to-gs-100-grace-science-s-gene-therapy-to-treat-ngly1-deficiency
- https://www.prnewswire.com/news-releases/andelyn-biosciences-partners-with-evolyra-therapeutics-for-the-clinical-manufacturing-of-gene-therapies-for-the-treatment-of-limb-girdle-muscular-dystrophies-302740699.html
- https://telanganatoday.com/a-clinical-trial-published-in-nejm-shows-stem-cell-based-living-pharmacy-treatment-may-eliminate-the-need-for-daily-insulin-in-type-1-diabetes-patients-most-participants-achieved-in
- https://www.roswellpark.org/newsroom/202604-roswell-park-launches-exclusive-cd83-car-t-cell-clinical-trial-patients-relapsed-or
- https://www.nature.com/articles/s41409-026-02858-5
- https://www.genengnews.com/topics/bioprocessing/car-t-cell-therapy-biomanufactured-by-cellares-infused-into-first-two-patients/
- https://themedicinemaker.com/issues/2026/articles/april/fda-fast-tracks-off-the-shelf-car-t-for-aggressive-t-cell-cancers/
- https://za.investing.com/news/company-news/meiragtx-to-present-3year-data-from-xerostomia-gene-therapy-trial-93CH-4210887
- https://www.springermedicine.com/gene-therapy/thalassemia/democratizing-the-cure-indigenous-innovations-and-the-future-of-/52284258